

Case discussion: VascuFlex 2-LOC/3-LOC in a long & complex fempop lesion

Erwin Blessing, FESC
SRH-Klinikum Karlsbad-
Langensteinbach
Germany

Disclosure

Speaker name:


Erwin Blessing

I have the following potential conflicts of interest to report:

- Consulting
- Employment in industry
- Stockholder of a healthcare company
- Owner of a healthcare company
- Other(s): Honorarium: B. Braun

I do not have any potential conflict of interest

Dissection: Mechanism of Action for Angioplasty




Lesions with dissections have a **TLR rate 3.5 times higher** than lesions without dissection¹

Current tools for dissection repair (stents) have limitations

Do we Need Implants?

Bailout Stent Rates across DCB Trials



Do we need a full metal jacket?

Sample Size	220	131	157	126	1406
Lesion Length [cm]	8,9	17,2	26,4	22,8	12,1
Total Occlusion	25,8%	34,0%	60,4%	100,0%	35,5%
Primary Patency (KM @ 360 days)	87,5%	88,7%	91,1%	85,3%	N/A

DCB Limitations: High rate of Provisional Stent

1. Tepe G et al., Circulation 2015
2. Brodmann M et al., JACC Cardiovasc Interv. 2017
3. Presented by Scheinert D. EuroPCR 2015
4. Presented by Tepe G Charing Cross 2016
5. Presented by Jaff M. VIVA 2016

FIGURE 2 Kaplan-Meier







TABLE 2 Lesion and Procedural Characteristics According to the Stenting Strategies

	Spot Stenting 129 Limbs	Long Stenting 67 Limbs	p Value*	p Value†
Mean lesion length, cm	25.7 ± 8.6	24.2 ± 7.8	0.225	0.224
Proximal SPA	107 (83)	52 (78)	0.365	0.364
Lesions with P2 or P3 segment involvement	21 (16)	15 (22)	0.295	0.262
Lesion type, TASC II			0.007	0.020
B	3 (2)	8 (12)		
C	25 (19)	14 (21)		
D	101 (78)	45 (67)		
Calcified lesion	36 (28)	24 (36)	0.254	0.258
Right side	57 (44)	33 (49)	0.499	0.483
Distal run-off vessels ≤1	45 (35)	28 (42)	0.343	0.338
Pre-procedural ABI	0.48 ± 0.17	0.45 ± 0.19	0.494	0.482
Use of re-entry device	5 (4)	5 (7)	0.314	0.284
Number of stents			<0.001	<0.001
1	112 (87)	16 (24)		
2	17 (13)	42 (63)		
3	0	9 (13)		
Stented length, cm	10.3 ± 3.6	24.6 ± 8.7	<0.001	<0.001
Mean stent diameter, mm	7.3 ± 0.7	6.5 ± 0.5	<0.001	<0.001
Mean femoral artery diameter, mm‡	6.2 ± 1.0	5.8 ± 0.9	0.010	0.011
Stent-to-artery ratio‡	1.2 ± 0.2	1.1 ± 0.2	0.232	0.331
Proximal stent diameter, mm			<0.001	<0.001
6	23 (18)	29 (43)		
7	54 (42)	32 (48)		
8	52 (40)	6 (9)		



Number at risk

Spot	81	68	61
Long	14	7	5
	12	6	2
	3	2	1



Number at risk

Spot	81	68	61
Long	14	7	5
	12	6	2
	3	2	1


stenting group. There was a
justment using inverse

Spot stenting – device options

Device	No. of stents	Stent length	Stent design	Radial force	Stent diameters	Sheath & guidewire
VascuFlex® Multi-LOC	6 stents	13 mm each	Nitinol, Closed Cell	High	5-8 mm	6F & 0.035"



VascuFlex® 2-LOC	2 stents	30 mm / 40 mm each	Nitinol, Open Cell	Medium	5-8 mm	6F & 0.035"
VascuFlex® 3-LOC	3 stents					



VascuFlex[®] 2-LOC/3-LOC – spot stenting in daily routine

- Spot Stenting Device
- 2 or 3 stents on one device
- Open cell design (like a typical stent device)
- Made for Fempop

- Stent-diameter: 5.0 – 8.0 mm
- Stent-length: 30 – 40 mm
- Shaft length: 80 / 130 cm

- The more common spot stenting device!

- Common stent architecture
- Longer stents
- 2/3 stents for more options in long lesions



Case presentation

62 year old male

Rutherford 3 right leg

Diabetes mellitus II (insulin therapy)

Arterial hypertension

Duplex and MRI:

long occlusion right SFA



Case presentation

Antegrade access right CFA

6 F sheath


Intraluminal vs. subintimal wire passage?



Reentry-Device?

Lesion preparation (focal force balloons, debulking)?


Drug coated balloons plus bail-out stenting?


Case presentation





Case presentation





Case presentation



13:11



13:46

Total procedure: 36 min
Fluoro: 9.1 min
Contrast: 100 ml

Conclusions

Complex femoropopliteal lesions are plagued by a high bail-out stent rate (mainly driven by dissections)

Drug eluting balloon angioplasty plus spotted stenting
→ leave as little behind as possible

VascuFlex® 2-LOC/3-LOC offers an easy-to-use spot stenting device

Case discussion: VascuFlex 2-LOC/3-LOC in a long & complex fempop lesion

Erwin Blessing, FESC
SRH-Klinikum Karlsbad-
Langensteinbach
Germany